New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 19, 2012
07:39 EDTBTX, GERNGeron acknowledges letter to its stockholders from BioTime
Geron (GERN) acknowledged the public release by BioTime (BTX) of a letter to Geron's stockholders regarding Geron's stem cell assets. Geron's Board of Directors has, since the announcement that Geron would be discontinuing its stem cell research and development programs, considered a number of alternatives with respect to such programs. Consistent with its fiduciary duties and responsibilities, and in consultation with its financial and legal advisors, Geron's Board of Directors will diligently review BioTime's proposal and act in a manner that the Board believes is in the best interests of Geron's stockholders. Stifel Nicolaus Weisel is acting as financial advisor and Weil, Gotshal & Manges LLP is acting as legal counsel to Geron in connection with the divestiture of Geron's stem cell assets.
News For GERN;BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
15:22 EDTGERNGeron volatility increases to 134
Geron overall option implied volatility of 134 is above its 26-week average of 106 according to Track Data, suggesting large price movement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use